AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...
The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab or eculizumab for paroxysmal ...
The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
Voydeya is a first-in-class, oral, factor D inhibitor. The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of ...
ASH 2025 highlighted many investigational agents for paroxysmal nocturnal hemoglobinuria (PNH) that may not reach clinical practice soon, notes Dr Jamile M. Shammo, though bispecific antibodies show ...
Treating Paroxysmal Nocturnal Hemoglobinuria: PNH is a rare, acquired hematologic disease characterized by complement-mediated hemolysis, fatigue, susceptibility to thrombosis, and bone marrow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results